Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAK | O14976 | 1/20 | 0.55 |
| ▸ | TNNI3K | Q59H18 | 7/20 | 0.53 |
| ▸ | BRAF | P15056 | 1/20 | 0.51 |
| ▸ | JAK1 | P23458 | 4/20 | 0.51 |
| ▸ | BRD4 | O60885 | 4/20 | 0.51 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.51 |
| ▸ | JAK3 | P52333 | 5/20 | 0.50 |
| ▸ | EGFR | P00533 | 5/20 | 0.50 |
| ▸ | JAK2 | O60674 | 4/20 | 0.50 |
| ▸ | RET | P07949 | 2/20 | 0.50 |
| ▸ | WEE1 | P30291 | 2/20 | 0.50 |
| ▸ | FLT3 | P36888 | 2/20 | 0.50 |
| ▸ | ALK | Q9UM73 | 2/20 | 0.50 |
| ▸ | SYK | P43405 | 2/20 | 0.50 |
| ▸ | BTK | Q06187 | 2/20 | 0.50 |
| ▸ | CDC7 | O00311 | 1/20 | 0.50 |
| ▸ | PLK4 | O00444 | 1/20 | 0.50 |
| ▸ | CHEK1 | O14757 | 1/20 | 0.50 |
| ▸ | AURKA | O14965 | 1/20 | 0.50 |
| ▸ | DCLK1 | O15075 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10261607 | 0.89 | JAK1 (0.59) | JAK1BRD4HDAC1JAK3EGFR | |
| SCHEMBL12279008 | 0.89 | TNNI3K (0.57) | TNNI3KBRAFJAK1BRD4JAK3 | |
| SCHEMBL10267408 | 0.88 | BRD4 (0.64) | GAKTNNI3KBRAFJAK1BRD4 | |
| SCHEMBL10259942 | 0.88 | BRD4 (0.63) | GAKTNNI3KBRAFJAK1BRD4 | |
| SCHEMBL10260564 | 0.88 | JAK3 (0.64) | JAK1BRD4JAK3EGFRJAK2 | |
| SCHEMBL309663 | 0.86 | JAK3 (0.49) | JAK1BRD4HDAC1JAK3EGFR | |
| SCHEMBL12111065 | 0.86 | JAK3 (0.49) | TNNI3KJAK1BRD4HDAC1JAK3 | |
| SCHEMBL301482 | 0.85 | JAK3 (0.48) | JAK1BRD4HDAC1JAK3EGFR | |
| SCHEMBL301681 | 0.85 | BRD4 (0.61) | GAKTNNI3KBRAFJAK1BRD4 | |
| SCHEMBL270501 | 0.84 | JAK1 (0.56) | GAKTNNI3KBRAFJAK1BRD4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1951684-B1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN INC (US) | 2016-07-13 | — | — | EP | disclosed |
| US-8138199-B2 | Use of bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2012-03-20 | — | — | US | disclosed |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | TARGEGEN, INC. (US) | 2011-11-03 | — | — | US | disclosed |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | TARGEGEN, INC. (US) | 2011-09-01 | — | — | US | disclosed |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | IMPACT BIOMEDICINES, INC. | 2009-11-05 | — | — | US | disclosed |
| US-7528143-B2 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2009-05-05 | — | — | US | disclosed |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-11-08 | — | — | US | disclosed |
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | TARGEGEN, INC. (US) | 2007-08-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070191405-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | GAK 111/4885TNNI3K 94/4885BRAF 40/4885 |
| US-20070259904-A1 | Bi-aryl meta-pyrimidine inhibitors of kinases | JAK2, TYK2, JAK3 | GAK 111/4885TNNI3K 94/4885BRAF 40/4885 |
| US-20090275582-A1 | Bi-Aryl Meta-Pyrimidine Inhibitors of Kinases | JAK2, TYK2, JAK3 | GAK 111/4885TNNI3K 94/4885BRAF 40/4885 |
| US-20110212077-A1 | BI-ARYL META-PYRIMIDINE INHIBITORS OF KINASES | JAK2, TYK2, JAK3 | GAK 111/4885TNNI3K 94/4885BRAF 40/4885 |
| US-20110269721-A1 | METHODS OF TREATING THALASSEMIA | JAK2, STAT5A, STAT5B | GAK 2608/4885TNNI3K 202/4885BRAF 3196/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.